EP3698776A1 — Tamper-resistant dosage form with immediate release and resistance against solvent extraction
Assigned to Gruenenthal GmbH · Expires 2020-08-26 · 6y expired
What this patent protects
The invention relates to a tamper-resistant pharmaceutical dosage form comprising a multitude of particles which comprise a pharmacologically active compound, preferably selected from opioids; a polyalkylene oxide having a weight average molecular weight within the range of from …
USPTO Abstract
The invention relates to a tamper-resistant pharmaceutical dosage form comprising a multitude of particles which comprise a pharmacologically active compound, preferably selected from opioids; a polyalkylene oxide having a weight average molecular weight within the range of from 200,000 g/mol to 2,000,000 g/mol, and a disintegrant; wherein the pharmacologically active compound is dispersed in a matrix comprising the polyalkylene oxide and the disintegrant; wherein the content of the disintegrant is more than 20 wt.-%, based on the total weight of the particles; wherein the content of the polyalkylene oxide is at least 25 wt.-%, based on the total weight of the particles; and wherein the dosage form provides under in vitro conditions immediate release of the pharmacologically active compound in accordance with Ph. Eur.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.